“Rohto is a leading skincare and eye-drop manufacturer trading at a steep discount to peers due to inefficient R&D spending and weak investor communications. While it missed its recent annual guidance, management's new mid-term plan aligns with the fund's suggestions to focus on core high-value businesses, presenting significant upside potential.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.